Publications and Funding

Recent Lab Publications:

Nelson LJ, Castro KE, Xu B, Li J, Dinh NB, Thompson JM, Woytash J, Kipp KR, Razorenova OV. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma. Cell Cycle. 2022 May;21(10):1103-1119. doi: 10.1080/15384101.2022.2041783. Epub 2022 Mar 4. PubMed PMID: 35240916; PubMed Central PMCID: PMC9037521.
__________
Thompson JM, Landman J, Razorenova OV. Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers. Small GTPases. 2020 Jan;11(1):32-38. doi: 10.1080/21541248.2017.1336193. Epub 2017 Jul 7. Review. PubMed PMID: 28632992; PubMed Central PMCID: PMC6959287.
__________
Thompson JM, Alvarez A, Singha MK, Pavesic MW, Nguyen QH, Nelson LJ, Fruman DA, Razorenova OV. Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism. Mol Cancer Ther. 2018 Aug;17(8):1781-1792. doi: 10.1158/1535-7163.MCT-17-1076. Epub 2018 May 2. PubMed PMID: 29720560; PubMed Central PMCID: PMC6072609.
__________
Wright HJ, Hou J, Xu B, Cortez M, Potma EO, Tromberg BJ, Razorenova OV. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6556-E6565. doi: 10.1073/pnas.1703791114. Epub 2017 Jul 24. PubMed PMID: 28739932; PubMed Central PMCID: PMC5559020.

 

PubMed link to full list of publications (updated regularly):

https://www.ncbi.nlm.nih.gov/sites/myncbi/1zKNkluJ9toA5/bibliography/41748639/public/?sort=date&direction=ascending

Current Funding: